UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

ABSTRACT:

Objectives

In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term might dramatically improve the cost effectiveness. The UK Risk-sharing Scheme (RSS) was established to ensure cost-effective provision by prospectively collecting disability-related data from UK-treated patients with MS and comparing findings to a natural history (untreated) cohort. However, deficiencies were found in the originally selected untreated cohort and the resulting analytical approach. This study aims to identify a more suitable natural history cohort and to develop a robust analytic

SUBMITTER: Palace J 

PROVIDER: S-EPMC3902459 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature